Signalling profile differences: Paliperidone versus risperidone

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 532-545

  Clarke, W P ^a   Chavera, T A ^a   Silva, M ^a   Sullivan, L C ^a   Berg, K A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

antipsychotics; biased agonism; dopamine; functional selectivity; GPCR; histamine; schizophrenia; serotonin

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; ADENYLATE CYCLASE; BETA ARRESTIN; BUTACLAMOL; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR; HYDROXYL GROUP; KETANSERIN; MEPYRAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PALIPERIDONE; QUINPIROLE; RECEPTOR SUBTYPE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ANIMAL CELL; ARTICLE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; REGULATORY MECHANISM;

ANTIPSYCHOTICS; BIASED AGONISM; DOPAMINE; FUNCTIONAL SELECTIVITY; GPCR; HISTAMINE; SCHIZOPHRENIA; SEROTONIN;

ADENYLATE CYCLASE; ANIMALS; ANTIPSYCHOTIC AGENTS; ARRESTINS; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HISTAMINE AGONISTS; HUMANS; ISOXAZOLES; MOLECULAR STRUCTURE; PYRIMIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D2; RECEPTORS, HISTAMINE H1; RISPERIDONE; SEROTONIN RECEPTOR AGONISTS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 84884541753     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12295     Document Type: Article

References (50)

1. Akam E, Strange PG, (2004). Inverse agonist properties of atypcial antipsychotic drugs. Biochem Pharmacol 67: 2039-2045.
2. Beaulieu J, Gainetdinov R, (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63: 182-217.
3. Berg K, Rowan M, Sanchez T, Silva M, Patwardhan A, Milam S, et al. (2011). Regulation of kappa-opioid receptor signaling in peripheral sensory neruons in vitro and in vivo. J Pharmacol Exp Ther 338: 92-99.
4. Berg KA, Clarke WP, (2006). Development of functionally selective agonists as novel therapeutic agents. Drug Discov Today Ther Strat 3: 421-428.
5. Berg KA, Clarke WP, Sailstad C, Saltzman A, Maayani S, (1994). Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Mol Pharmacol 46: 477-484.
6. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP, (1998). Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94-104.
7. Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP, (1999). Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 55: 863-872.
8. Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP, (2001a). RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 134: 386-392.
9. Berg KA, Stout BD, Maayani S, Clarke WP, (2001b). Differences in rapid desensitization of 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor-mediated phospholipase C activation. J Pharmacol Exp Ther 299: 593-602.
10. Berg KA, Evans KL, Cropper JD, Clarke WP, (2003). Temporal regulation of agonist efficacy at 5-hydroxytryptamine (5-HT)1A and 5-HT 1B receptors. J Pharmacol Exp Ther 304: 200-205.
11. Berg KA, Harvey JA, Spampinato U, Clarke WP, (2005). Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors. Trends Pharmacol Sci 26: 625-630.
12. Berg KA, Navailles S, Sanchez TA, Silva YM, Wood MD, Spampinato U, et al. (2006). Differential effects of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5- pyridyl]carbamoyl]-6-trifluoro methylindone (SB 243213) on 5- hydroxytryptamine(2C) receptor-mediated responses. J Pharmacol Exp Ther 319: 260-268.
13. Berg KA, Patwardhan AM, Sanchez TA, Silva YM, Hargreaves KM, Clarke WP, (2007). Rapid modulation of mu-opioid receptor signaling in primary sensory neurons. J Pharmacol Exp Ther 321: 839-847.
14. Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP, (2008). A conservative, single amino acid substitution in the second cytoplasmic domain of the h5-HT2C receptor alters both ligand-dependent and ligand-independent receptor signaling. J Pharmacol Exp Ther 324: 1084-1092.
15. Brea J, Masaguer C, Villazon M, Cadavid M, Ravina E, Fontaine F, et al. (2003). Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT2A and 5-HT2C receptor behaviors. Eur J Med Chem 38: 433-440.
16. Brink C, Harvey B, Bodenstein J, Venter D, Oliver D, (2004). Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. Br J Clin Pharmacol 57: 373-387.
17. Citrome L, (2007). Paliperidone: quo vadis? Int J Clin Pract 61: 653-662.
18. Clarke W, Berg K, (2010). Use of functional assays to detect and quantify functional selectivity. Drug Discov Today Technol 7: e31-e36.
19. Clarke WP, (2005). What's for lunch at the conformational cafeteria? Mol Pharmacol 67: 1819-1821.
20. Dolder C, Nelson M, Deyo Z, (2008). Paliperidone for schizophrenia. Am J Health Syst Pharm 65: 403-413.
21. Dopheide JA, (2008). Paliperidone: an improvement over risperidone? Am J Health Syst Pharm 65: 401.
22. Dremencov E, El Mansari M, Blier P, (2007). Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 194: 63-72.
23. Egan CT, Herrick-Davis K, Teitler M, (1998). Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286: 85-90.
24. Ereshefsky L, Mascarenas C, (2003). Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64 (Suppl. 16): 18-23.
25. Evans KL, Cropper JD, Berg KA, Clarke WP, (2001). Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components. J Pharmacol Exp Ther 297: 1025-1035.
26. Fleischhacker W, Gopal S, Lane R, Gassmann-Mayer C, Lim R, Hough D, et al. (2011). A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 15: 107-118.
27. Gray JA, Roth BL, (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33: 1100-1119.
28. Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D, (2007). Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology 52: 1106-1113.
29. Kapur S, Zipursky R, Jones C, Remington G, Houle S, (2000). Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514-520.
30. Kenakin T, (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. Faseb Journal 15: 598-611.
31. Kenakin T, (2007). Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72: 1393-1401.
32. Kenakin T, (2011). Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336: 296-302.
33. Lopez-Giminez J, Villazon M, Brea J, Loza M, Palacios J, Mengod G, et al. (2001). Multiple conformations of native and recombinant human 5-hydroxytrptamine (2A) receptors are labeled by aognists and discriminated by antagonists. Mol Pharmacol 60: 690-699.
34. MacDonald G, Bartolome J, (2010). A decade of progress in the discovery and development of 'atypical' antipsychotics. Prog Med Chem 49: 37-80.
35. Marion S, Weiner DM, Caron MG, (2004). RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2C receptor isoforms. J Biol Chem 279: 2945-2954.
36. Meltzer HY, Massey BW, Horiguchi M, (2012). Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13: 1572-1586.
37. Milligan G, Bond RA, (1997). Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18: 468-474.
38. Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, et al. (2007). Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321: 1054-1061.
39. Nyberg S, Farde L, Halldin C, Dahl M, Bertilsson L, (1995). D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152: 173-178.
40. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent (2007). Prescrire Int 16: 236-237.
41. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. (2012). A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 218-226.
42. Parra S, Bond RA, (2007). Inverse agonism: from a curiosity to accepted dogma, but is it clinically relevant? Curr Opin Pharmacol 7: 146-150.
43. Perez DM, Karnik SS, (2005). Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 57: 147-161.
44. Rauser L, Savage JE, Meltzer HY, Roth BL, (2001). Phsyiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69: 511-534.
45. Schotte A, Janssen P, Gommeren W, Luyten W, Van Gompet P, Lesage A, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.
46. Turkoz I, Bossie C, Lindenmayer J, Scooler N, Canuso C, (2011). Paliperidone ER and oral risperidone in patients with schizophrenia: a compoarative database analysis. BMC Psychiatry 11: 21.
47. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
48. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, et al. (2001). 5-hydroxytryptamine2A inverse agonists as antipsychotics. J Pharmacol Exp Ther 299: 268-276.
49. Wilbanks AM, Laporte SA, Bohn LM, Barak LS, Caron MG, (2002). Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. Biochemistry 41: 11981-11989.
50. Wong E, Nikam S, Shahid M, (2008). Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 9: 28-36.